278 related articles for article (PubMed ID: 33352993)
1. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
Pobbati AV; Rubin BP
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
Zhao B; Pobbati AV; Rubin BP; Stauffer S
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
Mills KR; Misra J; Torabifard H
J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
[TBL] [Abstract][Full Text] [Related]
4. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
5. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
7. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
8. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
9. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
[TBL] [Abstract][Full Text] [Related]
11. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
[TBL] [Abstract][Full Text] [Related]
12. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
14. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
[TBL] [Abstract][Full Text] [Related]
15. Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.
Kaan HYK; Sim AYL; Tan SKJ; Verma C; Song H
PLoS One; 2017; 12(6):e0178381. PubMed ID: 28570566
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
18. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
[TBL] [Abstract][Full Text] [Related]
19. Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex.
Che K; Pobbati AV; Seavey CN; Fedorov Y; Komar AA; Burtscher A; Ma S; Rubin BP
PLoS One; 2022; 17(4):e0266143. PubMed ID: 35417479
[TBL] [Abstract][Full Text] [Related]
20. Structure-based derivation and optimization of YAP-like coactivator-derived peptides to selectively target TEAD family transcription factors by hydrocarbon stapling and cyclization.
He B; Wu T; He P; Lv F; Liu H
Chem Biol Drug Des; 2021 Jun; 97(6):1129-1136. PubMed ID: 33283479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
